PRA Health Sciences (NASDAQ:PRAH) Hits New 12-Month High at $158.32

PRA Health Sciences, Inc. (NASDAQ:PRAH) shares reached a new 52-week high on Thursday . The company traded as high as $158.32 and last traded at $157.08, with a volume of 4836 shares traded. The stock had previously closed at $157.00.

PRAH has been the topic of a number of research reports. Mizuho boosted their target price on shares of PRA Health Sciences from $110.00 to $155.00 in a report on Friday, March 19th. KeyCorp reaffirmed a “sector weight” rating on shares of PRA Health Sciences in a research note on Monday, March 15th. Jefferies Financial Group lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, February 25th. Zacks Investment Research raised shares of PRA Health Sciences from a “sell” rating to a “hold” rating and set a $160.00 price objective on the stock in a research note on Tuesday, March 30th. Finally, Robert W. Baird increased their target price on shares of PRA Health Sciences from $130.00 to $145.00 and gave the stock an “outperform” rating in a research note on Thursday, January 21st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $122.89.

The company has a market cap of $10.13 billion, a P/E ratio of 45.91, a price-to-earnings-growth ratio of 2.26 and a beta of 1.24. The company’s 50-day moving average is $145.56 and its two-hundred day moving average is $123.19. The company has a quick ratio of 1.13, a current ratio of 1.13 and a debt-to-equity ratio of 0.95.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, February 24th. The medical research company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.31. PRA Health Sciences had a net margin of 7.09% and a return on equity of 22.21%. On average, analysts anticipate that PRA Health Sciences, Inc. will post 3.85 EPS for the current fiscal year.

In related news, CAO Christopher L. Gaenzle sold 3,136 shares of the firm’s stock in a transaction that occurred on Friday, January 8th. The shares were sold at an average price of $130.04, for a total value of $407,805.44. Following the sale, the chief accounting officer now directly owns 34,500 shares of the company’s stock, valued at $4,486,380. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. State of Michigan Retirement System boosted its holdings in PRA Health Sciences by 0.4% in the fourth quarter. State of Michigan Retirement System now owns 23,397 shares of the medical research company’s stock valued at $2,935,000 after acquiring an additional 100 shares in the last quarter. Janney Montgomery Scott LLC raised its position in PRA Health Sciences by 2.2% in the 4th quarter. Janney Montgomery Scott LLC now owns 5,332 shares of the medical research company’s stock worth $669,000 after buying an additional 115 shares during the last quarter. Panagora Asset Management Inc. raised its position in PRA Health Sciences by 14.1% in the 4th quarter. Panagora Asset Management Inc. now owns 1,208 shares of the medical research company’s stock worth $152,000 after buying an additional 149 shares during the last quarter. Truist Financial Corp raised its position in PRA Health Sciences by 3.7% in the 3rd quarter. Truist Financial Corp now owns 5,785 shares of the medical research company’s stock worth $587,000 after buying an additional 204 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in shares of PRA Health Sciences by 9.3% during the 4th quarter. Bessemer Group Inc. now owns 2,401 shares of the medical research company’s stock valued at $301,000 after purchasing an additional 205 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

PRA Health Sciences Company Profile (NASDAQ:PRAH)

PRA Health Sciences, Inc engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services.

Featured Article: Put Option Volume

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.